Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing-Based Comprehensive Tumor Profiling in Liquid Biopsy Samples.

The Journal of molecular diagnostics : JMD - 1 Jan 2024

Harter Johannes, Buth Eleonora, Johaenning Janina, Battke Florian, Kopp Maria, Zelba Henning, Schulze Martin, Koedding Jiri, Biskup Saskia

Abstract excerpt

Next-generation sequencing (NGS)-based comprehensive tumor profiling from liquid biopsy samples can significantly improve diagnosis and monitoring of tumors when high-quality tissue material is difficult to obtain. In addition, it offers the potential to capture the entire complexity of the tumor, which is particularly important for highly heterogeneous or metastatic tumors. Here, we report the findings of an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Liquid Biopsy

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 37865292
DOI: 10.1016/j.jmoldx.2023.10.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing-Based Comprehensive Tumor Profiling in Liquid Biopsy Samples.PMID 37865292Read ↗

A liquid biopsy-centered, pan-cancer, open next generation sequencing panel to support clinical decision-making (LION panel)Semantic proximity Read ↗

Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panelsSemantic proximity Read ↗

Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice.Semantic proximity Read ↗

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.Semantic proximity Read ↗

Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumorsSemantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNASemantic proximity Read ↗

Strategies for improving detection of circulating tumor DNA using next generation sequencing.Semantic proximity Read ↗

Analytical evaluation of circulating tumor DNA sequencing assays.Semantic proximity Read ↗

Genetic profiling of cancer with circulating tumor DNA analysis.Semantic proximity Read ↗

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.Semantic proximity Read ↗

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.